Your browser doesn't support javascript.
loading
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
Chan, Conrad E Z; Seah, Shirley G K; Chye, De Hoe; Massey, Shane; Torres, Maricela; Lim, Angeline P C; Wong, Steven K K; Neo, Jacklyn J Y; Wong, Pui San; Lim, Jie Hui; Loh, Gary S L; Wang, Dongling; Boyd-Kirkup, Jerome D; Guan, Siyu; Thakkar, Dipti; Teo, Guo Hui; Purushotorman, Kiren; Hutchinson, Paul E; Young, Barnaby E; Low, Jenny G; MacAry, Paul A; Hentze, Hannes; Prativadibhayankara, Venkateshan S; Ethirajulu, Kantharaj; Comer, Jason E; Tseng, Chien-Te K; Barrett, Alan D T; Ingram, Piers J; Brasel, Trevor; Hanson, Brendon John.
Afiliación
  • Chan CEZ; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Seah SGK; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Chye H; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Massey S; Department of Microbiology & Immunology and Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, United States of America.
  • Torres M; Department of Microbiology & Immunology and Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, United States of America.
  • Lim APC; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Wong SKK; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Neo JJY; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Wong PS; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Lim JH; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Loh GSL; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Wang D; Biological Defence Programme, DSO National Laboratories, Singapore, Singapore.
  • Boyd-Kirkup JD; Hummingbird Bioscience, Singapore, Singapore.
  • Guan S; Hummingbird Bioscience, Singapore, Singapore.
  • Thakkar D; Hummingbird Bioscience, Singapore, Singapore.
  • Teo GH; Life Science Institute, National University of Singapore, Singapore, Singapore.
  • Purushotorman K; Life Science Institute, National University of Singapore, Singapore, Singapore.
  • Hutchinson PE; Life Science Institute, National University of Singapore, Singapore, Singapore.
  • Young BE; National Centre for Infectious Diseases, Singapore, Singapore.
  • Low JG; Singapore General Hospital, Singapore, Singapore.
  • MacAry PA; Programme in Emerging Infectious Disease, Duke-National University of Singapore Medical School, Singapore, Singapore.
  • Hentze H; Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Prativadibhayankara VS; Experimental Drug Development Centre, Therapeutics Development, A*STAR Research Entities (ARES), Singapore, Singapore.
  • Ethirajulu K; Experimental Drug Development Centre, Therapeutics Development, A*STAR Research Entities (ARES), Singapore, Singapore.
  • Comer JE; Experimental Drug Development Centre, Therapeutics Development, A*STAR Research Entities (ARES), Singapore, Singapore.
  • Tseng CK; Department of Microbiology & Immunology and Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, United States of America.
  • Barrett ADT; Department of Microbiology & Immunology and Center of Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, United States of America.
  • Ingram PJ; Department of Pathology and Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, United States of America.
  • Brasel T; Hummingbird Bioscience, Singapore, Singapore.
  • Hanson BJ; Department of Microbiology & Immunology and Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, United States of America.
PLoS One ; 16(6): e0253487, 2021.
Article en En | MEDLINE | ID: mdl-34161386
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / SARS-CoV-2 / COVID-19 Límite: Animals / Female / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Singapur Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / SARS-CoV-2 / COVID-19 Límite: Animals / Female / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Singapur Pais de publicación: Estados Unidos